Dolutegravir inhibits HIV-1 Env evolution in primary human cells

AIDS

Volumn 29, Issue 6, 2015, Pages 659-665

  Mesplède, Thibault ^a   Moïsi, Daniela ^a   Oliveira, Maureen ^a   Ibanescu, Ilinca ^a   Ohnona, Freédeéric ^a   Brenner, Bluma ^a   Wainberg, Mark A ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Dolutegravir; Env; Evolution; Integrase strand transfer inhibitors; Raltegravir

Indexed keywords

AMINO ACID; DOLUTEGRAVIR; GLYCOPROTEIN GP 160; INTEGRASE; RALTEGRAVIR; VIRUS PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FUSED HETEROCYCLIC RINGS; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONSENSUS SEQUENCE; CONTROLLED STUDY; ENZYME INHIBITION; GENETIC CODE; GENETIC DISTANCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; HYPOTHESIS; PRIORITY JOURNAL; VIROGENESIS; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS MUTATION; VIRUS STRAIN; CELL CULTURE; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; MUTATION RATE; VIRUS CULTURE;

ANTI-HIV AGENTS; CELLS, CULTURED; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VARIATION; HETEROCYCLIC COMPOUNDS, 3-RING; HIV-1; HUMANS; MUTATION RATE; RALTEGRAVIR POTASSIUM; SERIAL PASSAGE;

EID: 84936937055     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000606     Document Type: Article

References (33)

1. Lathouwers E, De Meyer S, Dierynck I, Van de Casteele T, Lavreys L, de Bethune MP, Picchio G. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis. Antivir Ther 2011; 16:99-108.
2. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, noninferiority SPRING-2 study. Lancet 2013; 381:735-743.
3. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.N Engl J Med 2013; 369:1807-1818.
4. Elion R, Molina JM, Ramon Arribas Lopez J, Cooper D, Maggiolo F, Wilkins E, et al. A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results. J Acquir Immune Defic Syndr 2013; 63:494-497.
5. Wohl DA, Cohen C, Gallant JE, Mills A, Sax PE, Dejesus E, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr 2014; 65:e118-e120.
6. Clumeck N, Molina JM, Henry K, Gathe J, Rockstroh JK, DeJesus E, et al. A randomized, double-blind comparison of singletablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs. ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr 2014; 65:e121-e124.
7. Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised openlabel phase 3b study. Lancet 2014; 383:2222-2231.
8. Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, doubleblind, noninferiority trial. Lancet Infect Dis 2013; 13:927-935.
9. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, noninferiority SAILING study. Lancet 2013; 382:700-708.
10. Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 2014; 210:354-362.
11. Wainberg MA, Mesplede T, Raffi F. What if HIV were unable to develop resistance against a new therapeutic agent? BMC Med 2013; 11:249-254.
12. Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011; 55:813-821.
13. Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012; 86:2696-2705.
14. Wares M, Mesplede T, Quashie PK, Osman N, Han Y, Wainberg MA. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology 2014; 11:7-14.
15. Mesplede T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, et al. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 2013; 10:22-28.
16. Mesplede T, Osman N, Wares M, Quashie PK, Hassounah S, Anstett K, et al. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. J Antimicrob Chemother 2014; 69:2733-2740.
17. Mesplede T, Wainberg MA. Is resistance to dolutegravir possible when this drug is used in first-line therapy? Viruses 2014; 6:3377-3385.
18. Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, D'Arrigo R, et al. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis 2012; 205:557-567.
19. Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2013; 207:740-748.
20. Oliveira M, Mesplede T, Quashie PK, Moisi D, Wainberg MA. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS 2014; 28:813-819.
21. Jagodzinski LL, Wiggins DL, McManis JL, Emery S, Overbaugh J, Robb M, et al. Use of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 to assess the performance of viral RNA quantitation tests. J Clin Microbiol 2000; 38:1247-1249.
22. Michael NL, Herman SA, Kwok S, Dreyer K, Wang J, Christopherson C, et al. Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J Clin Microbiol 1999; 37:2557-2563.
23. Vahey M, Nau ME, Barrick S, Cooley JD, Sawyer R, Sleeker AA, et al. Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms. J Clin Microbiol 1999; 37:2533-2537.
24. Schader SM, Oliveira M, Ibanescu RI, Moisi D, Colby-Germinario SP, Wainberg MA. In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine. Antimicrob Agents Chemother 2012; 56:751-756.
25. Oliveira M, Brenner BG, Wainberg MA. Isolation of drugresistant mutant HIV variants using tissue culture drug selection. Methods Mol Biol 2009; 485:427-433.
26. Asahchop EL, Wainberg MA, Oliveira M, Xu H, Brenner BG, Moisi D, et al. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline. AIDS 2013; 27:879-887.
27. Nadai Y, Eyzaguirre LM, Constantine NT, Sill AM, Cleghorn F, Blattner WA, Carr JK. Protocol for nearly full-length sequencing of HIV-1 RNA from plasma. PLoS One 2008; 3:e1420.
28. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol 2013; 30:2725-2729.
29. Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2011; 55:4552-4559.
30. DeAnda F, Hightower KE, Nolte RT, Hattori K, Yoshinaga T, Kawasuji T, Underwood MR. Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics. PLoS One 2013; 8:e77448.
31. Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nature Med 2012; 18:1688-1692.
32. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, et al. Coevolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013; 496:469-476.
33. Bouvin-Pley M, Morgand M, Meyer L, Goujard C, Moreau A, Mouquet H, et al. Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies. J Virol 2014; 88:13910-13917.